(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 10.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Novo Nordisk (Ozempic)'s revenue in 2025 is $46,000,151,745.On average, 2 Wall Street analysts forecast NVO's revenue for 2025 to be $223,563,688,575,000, with the lowest NVO revenue forecast at $221,393,765,550,000, and the highest NVO revenue forecast at $225,733,611,600,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2026 to be $251,094,155,245,000, with the lowest NVO revenue forecast at $247,632,873,850,000, and the highest NVO revenue forecast at $254,819,380,650,000.
In 2027, NVO is forecast to generate $275,714,044,690,000 in revenue, with the lowest revenue forecast at $269,534,770,450,000 and the highest revenue forecast at $280,910,206,300,000.